Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Pacira BioSciences's total debt was $363.12M at Jun 30, 2026. For fiscal 2025 it was $372.19M, down 36.4% from the year before. The highest annual figure on record is $585.32M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $372.19M | -36.4% |
| FY2024 | Dec 31, 2024 | $585.32M | +393.8% |
| FY2016 | Dec 31, 2016 | $118.53M | -0.0% |
| FY2015 | Dec 31, 2015 | $118.53M | -1.2% |
| FY2014 | Dec 31, 2014 | $120.00M | 0.0% |
| FY2013 | Dec 31, 2013 | $120.00M | +376.4% |
| FY2012 | Dec 31, 2012 | $25.19M | -1.5% |
| FY2011 | Dec 31, 2011 | $25.58M | +2.1% |
| FY2010 | Dec 31, 2010 | $25.05M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $363.12M | -38.0% |
| Q1 FY2026 | Mar 31, 2026 | $367.66M | +210.2% |
| Q4 FY2025 | Dec 31, 2025 | $372.19M | – |
| Q3 FY2025 | Sep 30, 2025 | $376.72M | – |
| Q4 FY2024 | Dec 31, 2024 | $585.32M | – |
| Q4 FY2016 | Dec 31, 2016 | $118.53M | – |
See a number that looks wrong?